PT-141 (Bremelanotide) vs Semax & Selank
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Semax & Selank
A nootropic combination pairing two Russian-developed peptides for cognitive enhancement. Semax provides stimulating focus and neuroprotection while Selank offers anxiolytic and mood-stabilizing effects, creating a balanced cognitive enhancement stack.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | Semax & Selank |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Semax enhances BDNF expression and modulates dopamine and serotonin systems for improved focus, memory, and neuroprotection. Selank affects BDNF and GABA systems, providing anxiolytic effects and immune modulation. Together they support cognitive function while managing stress and anxiety. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Semax: 200-600mcg intranasally 2-3 times daily. Selank: 250-500mcg intranasally 2-3 times daily. Can be used together or alternated based on needs. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Primarily administered intranasally for rapid brain uptake. N-Acetyl versions (NA-Semax, NA-Selank) offer enhanced stability and potency. Can also be injected subcutaneously. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Semax may cause mild irritability or hair shedding. Selank may cause mild fatigue or nasal irritation. Both are generally well-tolerated. |
| Best For |